Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 22, 2025
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences held its 36th Annual General Meeting on August 22, 2025, via video conferencing, attended by 60 members. Three ordinary resolutions were passed with overwhelming shareholder support: adoption of audited financial statements for FY ended March 31, 2025 (99.999% in favour), re-appointment of Sudharani Jasti as Director retiring by rotation (99.996% in favour), and appointment of Secretarial Auditors (99.999% in favour). The Auditors' Report and Secretarial Audit Report contained no qualifications or adverse remarks. The meeting was chaired by Venkateswarlu Jasti, Chairman and Managing Director, with KFin Technologies serving as the e-voting platform provider.
This is a routine AGM outcome disclosure with all resolutions passing by near-unanimous shareholder approval (>99.99%), reflecting strong investor confidence. Clean audit reports and smooth governance proceedings suggest no immediate red flags for shareholders, though the filing is procedural in nature and unlikely to move the stock price.